Form 4: IN8BIO Director, Luba Greenwood, Reports Stock Option Grant

Director Luba Greenwood reports acquisition of stock options in IN8BIO, INC.

Summary

• Luba Greenwood, a director of IN8BIO, INC., filed a Form 4 disclosing a transaction.
• On May 8, 2025, Greenwood acquired stock options for 63,150 shares of common stock at an exercise price of $0.17.
• The options vest in equal monthly installments starting June 8, 2025, with full vesting by the next annual meeting, contingent on continued service.
• Following the transaction, Greenwood directly owns options for 63,150 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) which is generally viewed neutrally to positively as it incentivizes key personnel. There are no red flags or overtly negative aspects.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule described is typical, designed to incentivize long-term commitment.
• The exercise price is often set at or above the current market price at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director to work towards the company's success, benefiting employees and other stakeholders.

Key Dates

Keywords

IN8BIO, stock options, Form 4, director, Luba Greenwood, beneficial ownership, securities, transaction